Predicting drug metabolism: A site of metabolism prediction tool applied to the cytochrome P450 2C9

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2313-2324

  Zamora, Ismael ^a,d   Afzelius, Lovisa ^a,b   Cruciani, Gabriele ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF PERUGIA   (Italy)

^d NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CYTOCHROME P450 2C9; ETHINYLESTRADIOL; INDOMETACIN; IRBESARTAN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MESTRANOL; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PRODRUG; ZAFIRLUKAST;

ARTICLE; DRUG DESIGN; DRUG METABOLISM; ENZYME SUBSTRATE; OXIDATION; PREDICTION AND FORECASTING; SEQUENCE HOMOLOGY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; HUMANS; HYDROGEN; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038440502     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021104i     Document Type: Article

References (72)

1. Afzelius, L.; Zamora, I.; Ridderström, M.; Kalén, A.; Andersson, T. B.; Masimirembwa, C. Mol. Pharmacol. 2001, 59, 909-919.
2. Jones, J. P.; He, M.; Trager, W. F.; Rettie, A. E. Three-Dimensional Quantitative Structure-Activity Relationship for Inhibitors of Cytochrome P450 2C9. Drug Metab. Dispos. 1996, 24, 1-6.
3. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B.; Wikel, J.; Wrighton, S. Three- and Four Dimensional-Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2C9 Inhibitors. Drug Metab. Dispos. 2000, 28, 994-1002.
4. Rao, S.; Aoyama, R.; Schrag, M.; Trager, W. F.; Rettie, A.; Jones, P. J. A Refined 3-Dimensional QSAR of Cytochrome P450 2C9: Computational Predictions of Drug Interactions. J. Med. Chem. 2000, 43, 2789-2796.
5. Cruciani, G.; Pastor, M.; Clementi, S.; Clementi, S. GRIND(GRID Independent descriptors) in 3D Structure-Metabolism Relationships. In Rational Approaches to Drug Design: 13th European symposium on quantitative structure-activity relationships; Höltje, H.-D., Sippl W., Eds.; Prous Science, Barcelona, 2001; pp 251-261.
6. Korzekwa, K. R.; Grogan, J.; DeVito, S.; Jones, J. P. Electronic Models for Cytochrome P450 Oxidations. Adv. Exp. Med. Biol. 1996, 38, 361-369.
7. Lewis, D. F.; Dickins, M.; Eddershaw, P. J.; Tarbit, M. H.; Goldfarb, P. S. Cytochrome P450 Substrate specificities, Substrate Structural Templates and Enzyme Active Site Geometries. Drug Metab. Drug Interact. 1999, 15, 1-49.
8. De Groot, M. J.; Ackland, M.; Horne, V.; Alexander, A.; Barry, J. Novel Approach to Predicting P450 Mediated Drug Metabolism. Development of Combined Protein and Pharmacophore Model for CYP2D6. J. Med. Chem. 1999, 42, 4062-4070.
9. Jones, B. C.; Hawksworth, G.; Horne, V. A.; Newlands, A.; Morsman, J.; Tute, M. S.; Smith, D. A. Putative Active Site Template Model for Cytochrome P450 2C9 (Tolbutamide Hydroxylase). Drug Metab. Dispos. 1996, 24, 260-266.
10. Mancy, A.; Broto, P.; Dijols, S.; Dansette, P. M.; Mansuy, D. The Substrate Binding Site of Human Liver Cytochrome P450 2C9: An Approach Using Designed Tienilic Acid Derivatives and Molecular Modeling. Biochemistry 1995, 34, 10365-10375.
11. Korzekwa, K. R.; Jones, J. P.; Gillette, J. R.; Theoretical Studies on Cytochrome P-450 Mediated Hydroxylation: A Predictive Model for Hydrogen Atom Abstractions, J. Am. Chem. Soc. 1990, 112, 7042.
12. Ridderström, M.; Zamora, I.; Fjäström, O.; Andersson, T. B. Analysis of Selective Regions in the Active Sites of Human CYP 2C8, 2C9, 2C18 and 2C19 Homology models Using GRID/CPCA, J. Med. Chem. 2001, 44, 4072-4081.
13. Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Mammalian Microsomal Cytochrome P450 Monooxygenase: Structural Adaptations for Membrane Binding and Functional Diversity. Mol. Cell 2000, 5, 121-131.
14. Schlichting, I.; Berebdzen, J.; Chu, K.; Stock, A. M.; Maves, S. A.; Benson, D. E.; Sweet, R. M.; Ringe, D.; Petsko, G. A.; Sligar, S. G. The Catalytic Pathway of Cytochrome P450cam at Atomic Resolution. Science 2000, 287, 1615-1622.
15. Transon, C.; Leemann, T.; Vogt, N.; Dayer PIn vivo inhibition profile of cytochrome P450tb (CYP2C9) by (±)-fluvastatin. Clin. Pharmacol. Ther. 1995, 58, 412-417.
16. Poli-Scaife, S.; Attias, R.; Dansette, P. M.; Mansuy, D. The substrate binding site of human liver cytochrome P450 2C9. Biochemistry 1997, 36, 12672-12682.
17. Hamman, M. A.; Thompson, G. A.; Hall, S. D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharm. 1997, 54, 33-41.
18. Miners, J. O.; Coulter, S.; Tukey, R. H.; Veronese, M. E.; Birkett, D. J. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem. Pharmacol. 1996, 51, 1003-1008.
19. Tracy, T. S.; Marra, C.; Wrighton, S. A.; Gonzalez, F. J.; Korzekwa, K. R. Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem. Pharmacol. 1996, 52, 1305-1309.
20. Rettie, A. E.; Korsekwa, K. R.; Kunze, K. L.; Lawrence, R. F.; Eddy, A. C.; Aoyama, T.; Gelboin, H. V.; Gonzalez, F. J.; Trager W. F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 1992, 5, 54-59.
21. Thijssen, H. H.; Flinois, J. P.; Beaune, P. H. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos. 2000, 28, 1284-1290.
22. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857.
23. GRID V.20, Molecular Discovery Ld, 2001 (http: www.moldiscovery.com).
24. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking J. Mol. Biol. 1997, 267, 727-748.
25. Pastor, M.; Cruciani, G.; McLay, I.; Pickett, S.; Clementi, S. GRid-INdependent Descriptors (GRIND): A Novel Class of Alignment-Independent Three-Dimensional Molecular Descriptors. J. Med. Chem. 2000, 17, 3233-3243.
26. CONCORD, Tripos Associates Inc., St Louis, MO.
27. Sadowski, J. A Hybrid Approach for Addressing Ring Flexibility in 3D Database Searching. J Comput.-Aided Mol. Des. 1997, 11, 53-60.
28. Monte Carlo Search, Tripos Associates Inc., St. Louis, MO (http:// www.tripos.com).
29. McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design J. Comput.-Aided Mol. Des. 1997, 11 (4), 333-344.
30. Amat, L.; Carbó-Dorca, R. Fitted Electronic Density Functions from H to Rn for Use in Quantum Similarity Measures: Cisdiamminedichloroplatinum(II) Complex as an Application Example. J. Comput. Chem. 1999, 20 (9), 911-920.
31. ISIS BASE, Metabolite database, MDL Information Systems Inc., San Leandro, CA.
32. Schmider, J.; Greenblatt, D. J.; von Moltke, L. L.; Karsov, D.; Vena, R.; Friedman, H. L.; Shader, R. I. Biotransformation of Mestranol to Ethinyl Estradiol In Vitro: The Role of Cytochrome P-450 2C9 and Metabolic Inhibitors. J. Clin. Pharmacol. 1997, 37 (3), 193-200.
33. Nakajima, M.; Inoue, T.; Shimada, N.; Tokudome, S.; Yamamoto, T.; Kuroiwa, Y. Cytochrome P450 2C9 Catalyzes Indomethacin O-Demethylation in Human Liver Microsomes. Drug Metab. Dispos. 1998, 26 (3), 261-266.
34. Blanck, C.; Mancini, J. A.; Lau, C. K.; Prasit, P.; Vickers, P. J. 1-Aroyl-3-indolyl alkanoic acids and derivatives. Thereof useful as anti-antiinflammatory agents. US 5,436,265, 1993.
35. Savidge, R. D.; Bui, K. H.; Birmingham, B. K.; Morse, J. L.; Spreen, R. C. Metabolism and Excretion of Zafirlukast in Dogs, Rats, and Mice. Drug Metab. Dispos. 1998, 26 (11), 1069-1076.
36. Grimm, S. W.; Stams, K. R.; Aaron, E. J. Zafirlukast is a Substrate for CYP2C9 and an Inhibitor of CYP2C9 and CYP3A In vitro. Int. Soc. Study Xenobiot. Proc. 1996, 10, 392-401.
37. Shader, R. I.; Granda, B. W.; von Moltke, L. L.; Giancarlo, G. M.; Greenblatt, D. J. Inhibition of Human Cytochrome P450 Isoforms In Vitro by Zafirkulast. Biopharm., Drug Dispos. 1999, 20, 385-388.
38. Brown, M. F.; Marfat, A. Indole Carbamates As Leukotriene Antagonists. WO 97/1751, 1997.
39. Merritt, H. H.; Putnam, T. Sodium Diphenyl hydantoinate in treatment of convulsive disorder. J. Am. Med. Assoc. 1938, 111, 1068-1073.
40. Zhou, L. X.; Pihlstrom, B.; Hardwick, J. P.; Park, S. S.; Wrighton, S. A.; Holtzman, J. L. Metabolism of Phenytoin by the Gingiva of Normal Humans: The Possible Role of Reactive Metabolites of Phenytoin in the Initiation of Gingival Hyperplasia. Clin. Pharmacol. Ther. 1996, 60 (2), 191-198.
41. Caraco, Y.; Muszkat, M.; Wood, A. J. J. Phenytoin Metabolic Ratio: a Putative Probe of CYP2C9 Activity. Clin. Pharmacol. Ther. 2000, 67 (2), 98-99.
42. Veronese, M. E.; Doecke, C. J.; Mackenzie, P. I.; McManus, M. E.; Miners, J. O.; Rees, D. L.; Gasser, R.; Meyer, U. A.; Birkett, D. J. Site-Directed Mutation Studies of Human Liver Cytochrome P-450 Isoenzymes in the CYP2C Subfamily. Biochem. J. 1993, 289, 533-538.
43. Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Role of Cytochrome P4502C9 in Irbesartan Oxidation by Human Liver Microsomes. Drug Metab. Dispos. 1999, 27 (2), 288-296.
44. Davi, H.; Tronquet, C.; Miscoria, G.; Perier, L.; Dupont, P.; Caix, J.; Simiand, J.; Berger, Y. Dispotition of Irbesartan, an Angiotensin II AT1-Receptor Antagonist, in Mice, Rats, Rabbits, and Macaques. Drug Metab. Dispos. 2000, 28 (1), 79-88.
45. McGurk, K. A.; Remmel, R. P.; Hosagrahara, V. P.; Tosh, D.; Burchell, B. Reactivity of Mefenamic Acid 1β-o-Acyl Glucuronide with Proteins In Vitro and Ex Vivo. Drug Metab. Dispos. 1996, 24 (8), 842-849.
46. Gorski, J. C.; Hall, S. D.; Becker, P.; Affrime, M. B.; Cutler, D. L.; Haehner-Daniels, B. In Vivo Effects of Interleukin-10 on Human Cytochrome P450 Activity. Clin. Pharmacol. Ther. 2000, 67 (1), 32-43.
47. Thijssen, H. H.; Verkooijen, I. W.; Frank, H. L. The Possession of the CYP2C9*3 Allele is Associated with Low Dose Requirement of Acenocoumarol. Pharmacogenetics 2000, 10 (8), 757-760.
48. Nakamura, A.; Hirota, T.; Morino, A.; Shimada, T.; Uematsu, T.; N-Oxidation of Irsogladine by the CYP2C Subfamily in the Rat, Dog, Monkey and Man. Xenobiotica 1997, 27 (10), 995-1003.
49. Bort, R.; Ponsoda, X.; Carrasco, E.; Gomez-Lechon, M. J.; Castell, J. V. Metabolism of Aceclofenac in Humans. Drug Metab. Dispos. 1996, 24 (8), 834-841.
50. Taburet, A. M.; Lecointre, K.; Furlan, V.; Goujard, C.; Delfraissy, J. F.; Lack of Effect of HIV Protease Inhibitors on Sulfamethoxazole Hydroxylamine Production. Clin. Pharmacol. Ther. 1999, 65 (2), 136-137.
51. Hultin, T. A.; Lihotz, L. A.; Scatina, J. Comparative Metabolism of Tasosartan in Mice, Rats, Dogs and Monkeys. Int. Soc. Study Xenobiot. Proc. 1997, 11, 226-227.
52. Taguchi, K.; Konishi, T.; Nishikawa, H.; Kitamura, S. Identification of Human Cytochrome P450 Isoforms Involved in the Metabolism of S-2[4-(3-methyl-2-thienyl)phenyl]propionic Acid. Xenobiotica 1999, 29 (9), 899-907.
53. Chiba, M.; Xu, X.; Nishime, J. A.; Balani, S. K.; Lin, J. H. Hepatic Microsomal Metabolism of Montelukast, a Potent Leukotriene D4 Receptor Antagonist, in Humans. Drug Metab. Dispos. 1997, 25 (9), 1022-1031.
54. Stresser, D. M.; Kupfer, D. Prosubstrates of CYP3A4, the Major Human Hepatic Cytochrome P450. Transformation into Substrates by Other P450 Isoforms. Biochem. Pharmacol. 1998, 55 (11), 1861-1871.
55. Oritani, H.; Mori, K.; Watanabe, T.; Higuchi, S. Species Differences in the In Vitro Metabolism of YM440, Anti-Diabetic Drug. Int. Soc. Study Xenobiot. Proc. 1999, 14, 56-57.
56. Tang, C.; Shou, M.; Mei, Q.; Rushmore, T. H.; Rodrigues, A. D. Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor. J. Pharmacol. Exp. Ther. 2000, 293 (2), 453-459.
57. Bort, R.; Mace, K.; Boobis, A.; Gomez-Lechon, M.-J.; Pfeifer, A.; Castell, J. Hepatic Metabolism of Diclofenac: Role of Human CYP in the Minor Oxidative Pathways. Biochem Pharmacol. 1999, 58 (5), 787-796.
58. Lill, J. S.; O'Sullivan, T.; Bauer, L. A.; Horn, J. R.; Carithers, R., Jr.; Strandness, D. E.; Lau, H.; Chan, K.; Thakker, K. Pharmacokinetics of Diclofenac Sodium in Chronic Active Hepatitis and Alcoholic Cirrhosis. J. Clin. Pharmacol. 2000, 40 (3), 250-257.
59. Yamazaki, H.; Inoue, K.; Chiba, K.; Ozawa, N.; Kawai, T.; Suzuki, Y.; Goldstein, J. A.; Guengerich, F. P.; Shimada, T. Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes. Biochem Pharmacol. 1998, 56 (2), 243-251.
60. Frye, R. F.; Tracy, T. S.; Hutzler, J. M.; Korzekwa, K. R.; Cannon, Y.; Pauli, M.; Huang, S. M.; Branch, R. A. Flurbiprofen as a Selective In Vivo Probe of CYP2C9 Activity. Clin. Pharmacol. Ther. 2000, 67 (2), 109-115.
61. Tracy, T. S.; Rosenbluth, B. W.; Wrighton, S. A.; Gonzales, F. J.; Korzekwa, K. R. Role of Cytochrome P450 2C9 and an Allelic Variant in the 4′-Hydroxylation of (R)- and (S)-Flurbiprofen, Biochem. Pharmacol. 1995, 49 (9), 1269-1275.
62. Draper, A. J.; Hammock, B. D. Identification of CYP2C9 as a Human Liver Microsomal Linoleic Acid Epoxygenase. Arch. Biochem. Biophys. 2000, 376 (1), 199-205.
63. Hutzler, J. M.; Tracy, T. S. Activation of CYP2C9 by Dapsone and Analogues. Drug Metab. Rev. 2000, 32, Suppl 2, 217.
64. Kohl, C.; Steinkellner, M. Prediction of Pharmacokinetic Drug/Drug Interactions from In Vitro Data: Interactions of the Nonsteroidal Antiinflammatory Drug Lornoxicam with Oral Anticoagulants. Drug Metab. Dispos. 2000, 28 (2), 161-168.
65. Weaver, R. J.; Dickins, M.; Burke, M. D. Hydroxylation of the Antimalarial Drug 58C80 by CYP2C9 in Human Liver Microsomes: Comparison with Mephenytoin and Tolbutamide Hydroxylations. Biochem. Pharmacol. 1995, 49 (7), 997-1004.
66. Yasar, U.; Tybring, G.; Hidestrand, M.; Oscarson, M.; Ingelman-Sundberg, M.; Dahl, M. L.; Eliasson, E. Role of CYP2C9 Polymorphism in Losartan Oxidation Drug Metab. Dispos. 2001, 29, 1051-1056.
67. He, M.; Korzekwa, K. R.; Jones, J. P.; Rettie, A. E.; Trager, W. F. Structural Forms of Phenprocoumon and Warfarin that are Metabolized at the Active Site of CYP2C9. Arch. Biochem. Biophys. 1999, 372 (1), 16-28.
68. Zhang, Z.-Y.; King, B. M.; Saxton, P.; Wong, Y. N. Validation of a LC/MS/MS Assay for the Determination of 6-, 7-, 8-, and 10-Hydroxywarfarin in Liver Microsomes. Drug Metab. Rev. 2000, 32, Suppl 2, 174.
69. Fischer, V.; Johanson, L.; Heitz, F.; Tullman, R.; Graham, E.; Baldeck, J.-P.; Robinson, W. T. The 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions. Drug Metab. Dispos. 1999, 27 (3), 410-416.
70. Tang, C.; Shou, M.; Rodrigues, A. D. Substrate-Dependent Effect of Acetonitrile on Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) Activity, Drug Metab. Dispos. 2000, 28 (5), 567-572.
71. Tang, W.; Stearns, R. A.; Wang, R. W.; Chiu, S.-H.; Baillie, T. A. Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac, Chem. Res. Toxicol. 1999, 12 (2), 192-199.
72. Lill, J. S.; O'Sullivan, T.; Bauer, L. A.; Horn, J. R.; Carithers, R.; Strandness, D. E.; Lau, H.; Chan, K.; Thakker, K. Pharmacokinetics of diclofenac sodium in chronic active hepatitis and alcoholic cirrhosis. J. Clin. Pharmacol. 2000, 40, 250-257.